Directorio

We are doing this study to find out if an investigational drug called HM43239 (the study drug) is a safe and effective option for people who have AML that came back after remission or did not respond to standard treatments. We also want to find out what dose of the study drug works best for most patients.

We are doing this study to learn more about children with atrioventricular septal defect. We hope to improve care for patients with this condition in the future.

We are doing this study to find out if breathing exercises can improve lung function for kids who have asthma.

This study has several parts. First, there is a screening period that can last up to 42 days. After that, people are randomly placed into different groups to start treatment. The main part of the study lasts 24 weeks, and doctors will check how the heart is doing at the end of that time. If someone finishes the first part and is still taking the study medicine, they may be placed into a new group for another 24 weeks of treatment. After that, there is a safety check that lasts 12 weeks to make sure everything is okay after the medicine ends.

We are doing this study to find out if an experimental drug called pegozafermin (the study drug) is a safe and effective option for people with Metabolic Dysfunction Associated Steatohepatitis (MASH).

If you decide to participate in this study, you will have a screening visit to see if you meet the criteria to be included in this study. If you are eligible, you will proceed to the study drug period. During this period, you will:

• Take the study drug tablets by mouth at about the same time each morning and within 30 minutes of finishing your breakfast for the first 15 days
• After the first 15 days, continue to take the study drug by mouth at approximately the same time every day, within 30 minutes of finishing a meal (breakfast, lunch, or dinner) of your choice

• Blood draws
• Imaging tests (CT, PET/CT and MRI)
• ECG

We are doing this study to find out if an experimental drug called XEN1101 (the study drug) is a safe and effective option for people who have epilepsy and are experiencing generalized tonic clonic seizures.

This study lasts for about 41 weeks. It starts with a screening period, followed by around 6 months of taking either the study medicine or a placebo, and ends with a follow-up visit. People who join will be randomly chosen to get either a low dose or high dose of the medicine called PKN605, or a placebo, which is a pill that does not have any medicine in it. During the study, participants will go to the clinic regularly. They will wear a heart monitor patch, use a small device at home to check their heart, and have blood tests and other health checks. These tests help doctors learn how the medicine works and if it is safe.